While the US election may still be disputed at the presidential level, there is no doubt that the medical cannabis sector was a winner. Ballot initiatives to legalise medical and/or recreational cannabis were passed in five states. Most significantly, New Jersey legalised cannabis for recreational use (it already permits the drug for medical purposes); this is expected to create a domino effect in neighbouring states on the heavily populated eastern seaboard.
As the sector gathers momentum in the US, the stage is set for the rest of the world to follow it on the path of legalising medical cannabis. Share prices have reacted positively to these developments but there is still tremendous upside.
Supplying the greenhouse
Hydroponics retailer GrowGeneration’s (Nasdaq: GRWG) expansion is directly tied to the proliferation of the US cannabis trade. The group’s products range from lighting fixtures and seeds to humidifiers. All large operators turn to GRWG to service their cultivation operations. The company exceeded revenue expectations in the third quarter of 2020 and has continually raised its sales guidance throughout the year as growth has been propelled by several tailwinds.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The industry is fragmented and GRWG has established itself as a reliable supplier for major operators across many regional markets in the US. We expect GRWG’s success to continue as the current environment of state-level cannabis legalisation supports long-term revenue growth trends.
Despite the challenges associated with Covid-19, Britain’s GW Pharmaceuticals (Nasdaq: GWPH) continues to enjoy increased adoption of its cannabis-derived drugs. Epidiolex meets a serious need in the field of epilepsy and the company expects strong growth for the treatment over the next few months.
The company has started advanced programmes for the treatment of multiple-sclerosis spasticity. It recently decided to accelerate several clinical-stage pipeline trials in this field. The current revenue base continues to grow thanks to the epilepsy treatment, but with its pace of research and development, GW Pharmaceuticals is well positioned to be a leader in several cannabis-derived drugs in the near future.
A saviour in the property sector
An interesting by-product of the current legal regime of cannabis in the US is the emergence of Real Estate Investment Trusts (Reits) as a source of financing in an industry hampered by regulations – the drug remains illegal at the federal level. With limited access to capital, the US cannabis industry has struggled to keep up with exponential demand; buying land and property for its production facilities has often proved problematic.
But it has found a saviour in the form of Industrial Innovative Properties (NYSE: IIPR). The group buys and then leases out properties to pot firms, helping them cut capital costs and make the most out of limited resources.
The current set of leases will be serviced at some of the highest rental rates for industrial properties in the country, reflecting the risk inherent in the tenants’ industry, but this also means investors are willing to ascribe a higher valuation to IIPR than to traditional Reits.
-
Will HMRC block money market funds from the stocks and shares ISA allowance?Cautious investors looking for cash-like returns could be prohibited from using money market funds in a stocks and shares ISA under new ISA rules from HMRC. What could it mean for you?
-
Nationwide: House price growth slows but market remained resilient despite Budget worriesThe average price of a house in the UK was £272,998 in November, as annual house price growth slowed to just 1.8%, Nationwide said.
-
Big Short investor Michael Burry closes hedge fund Scion CapitalProfile Michael Burry rightly bet against the US mortgage market before the 2008 crisis. Now he is worried about the AI boom
-
The global defence boom has moved beyond Europe – here’s how to profitOpinion Tom Bailey, head of research for the Future of Defence Indo-Pac ex-China UCITS ETF, picks three defence stocks where he'd put his money
-
Profit from a return to the office with WorkspaceWorkspace is an unloved play on the real estate investment trust sector as demand for flexible office space rises
-
New frontiers: the future of cybersecurity and how to investMatthew Partridge reviews the key trends in the cybersecurity sector and how to profit
-
An “existential crisis” for investment trusts? We’ve heard it all before in the 70sOpinion Those fearing for the future of investment trusts should remember what happened 50 years ago, says Max King
-
8 of the best properties for sale with wildlife pondsThe best properties for sale with wildlife ponds – from a 16th-century house in the Ashdown Forest, to a property on Pembrokeshire’s Preseli Hills
-
Why a copper crunch is loomingMiners are not investing in new copper supply despite rising demand from electrification of the economy, says Cris Sholto Heaton
-
Where to look for Christmas gifts for collectors“Buy now” marketplaces are rich hunting grounds when it comes to buying Christmas gifts for collectors, says Chris Carter
